Business Wire

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Share

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005340/en/

Under the terms of the agreement, Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

“AAT-associated liver disease is a devastating condition for which there are no approved therapies. With its RNAi-based mechanism of action, ARO-AAT has the potential to treat the underlying cause of AATLD, thereby helping patients avoid the need for liver transplantation and associated co-morbidities,” said Asit Parikh, M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit at Takeda. “We are excited to collaborate with Arrowhead to bring forward this exciting late-stage liver asset for the Alpha-1 community as part of our growing GI portfolio.”

“Takeda’s global presence and experience with payers and regulators in the rare disease and GI therapy space, combined with its long history serving the Alpha-1 community make it the ideal partner for ARO-AAT. It is well-positioned to work with the patient and medical community to help meet the severe unmet need of patients with Alpha-1 liver disease,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “This agreement also supports our strategy of using partnering selectively to continue to invest in our Targeted RNAi Molecule (TRiMTM) platform and the growing pipeline of RNAi therapeutics targeting diverse tissue types, while focusing our commercial organization on opportunities in two key areas of cardiometabolic and pulmonary.”

About Alpha-1 Antitrypsin-Associated Liver Disease

Alpha-1 Antitrypsin-Associated Deficiency (AATD) is a rare genetic disorder associated with liver disease in children and adults and pulmonary disease in adults. AATD is estimated to affect 1 per 3,000-5,000 people in the United States and 1 per 2,500 in Europe. The protein AAT is primarily synthesized and secreted by liver hepatocytes. Its function is to inhibit enzymes that can break down normal connective tissue. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein. The mutant protein cannot be effectively secreted and accumulates in globules inside the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.

Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and liver disease. Lung disease is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available cure.

About ARO-AAT

ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow it to regenerate and repair.

Takeda in Gastroenterology

We believe that GI and liver diseases are not just life disrupting conditions, but diseases that can impact a patient’s quality of life.1,2 Beyond a fundamental need for effective treatment options, we understand that improving patients’ lives also depends on their needs being recognized. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides in addressing GI patient needs with treatments for inflammatory bowel disease (IBD), acid-related diseases, short bowel syndrome (SBS), and motility disorders. We are making significant strides toward closing the gap on new areas of unmet needs for patients who have celiac disease, eosinophilic esophagitis, alpha-1 antitrypsin-associated liver disease, Crohn’s disease, and acute pancreatitis, among others. Together with researchers, patient groups and more, we are working to advance scientific research and clinical medicine in GI.

Arrowhead Conference Call and Webcast Information

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 1790033.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 1790033.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

References:


1 Center for Drug Evaluation and Research (CDER) & the FDA. The Voice of the Patient/Functional Gastrointestinal Disorder; 2016. https://www.fda.gov/media/95140/download

2 Jones R, et al. Management of common gastrointestinal disorders: quality criteria based on patients’ views and practice guidelines. Br J Gen Pract. 2009; 59(563):e199-208.

Contact information

Takeda Media:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Chris Stamm
chris.stamm@takeda.com
+1 (617) 374-7726

Arrowhead Investors:
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com

OR

LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com

Arrowhead Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361
jo@lifescicomms.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ergomotion Announces Opening of First Manufacturing Facility in North America29.10.2020 22:28:00 CETPress release

Ergomotion, part of the Keeson Technology Group and the largest manufacturer of adjustable bases worldwide, will open a 250,000 square foot manufacturing facility in Ciudad Juárez, Chihuahua, the company’s first assembly plant in North America. The expansion was fueled by the decision to increase product capabilities, oversee manufacturing functions, and ultimately to stay closer to Ergomotion’s customer base in the United States. “We see a prime opportunity with the North America expansion to enhance the customer service experience in the U.S.,” says Johnny Griggs, Chief Operating Officer at Ergomotion. “Our goal is to provide our partners with world class manufacturing and supply chain and to help grow and strengthen their business. We’re excited to partner with Ciudad Juárez to expand our manufacturing capabilities and make this project viable and successful.” Ergomotion is making a significant investment that will allow for the creation of 400 jobs, within the local economy. The Ju

IDEMIA Launches Converged Card to Enable Financial Inclusion with Identity and Payment Card Solution29.10.2020 17:45:00 CETPress release

IDEMIA, a global leader in identity and security solutions and the number one provider of driver’s licenses in the U.S., today announced the development of a Converged Card solution in partnership with Mastercard, allowing cardholders to safely and securely shop for everyday essentials. The solution will help bring more people into the formal economy in the U.S. who currently have limited or no access to financial services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005916/en/ IDEMIA Launches Converged Card to Enable Financial Inclusion with Identity and Payment Card Solution (Photo: Business Wire) Converged Card1 is a state-issued driver’s license or identification with a payment credential. This card or digital application will support state-subsidized programs, including unemployment benefits, housing and utility assistance, and tax refunds, allowing the government to automatically reach people that need funding

Airship Named a Leader in the 2020 Gartner Magic Quadrant for Mobile Marketing Platforms29.10.2020 16:34:00 CETPress release

Customer engagement companyAirship today announced that it has been named a Leader by Gartner, Inc. in its 2020 Magic Quadrant for Mobile Marketing Platforms.1 Among 13 vendors evaluated, Airship was positioned highest in its ability to execute and furthest to the right for its completeness of vision for the second consecutive year. A complimentary copy of the report is available from Airship. “Airship’s long held global leadership in customer engagement is experiencing dramatic acceleration, as new mobile-first capabilities like Airship Journeys make it much simpler and more effective to grow customer lifetime value in the omnichannel era. I believe Airship’s latest innovations, as well as expansions to experimentation and commerce, are already recognized as major beneficial differentiators in comprehensive evaluations like Gartner’s Magic Quadrant and Critical Capabilities reports,” said Brett Caine, CEO and president, Airship. “As mobile becomes increasingly vital for brands and the

myPOS Turns Smartphones Into POS Terminals29.10.2020 16:02:00 CETPress release

Business professionals can now take card payments directly on their Android phone with the new Soft POS solution myPOS Glass by the European fintech provider myPOS (www.mypos.com). The innovative mobile app enables payments with contactless cards and smart accessories directly on a mobile Android phone. The accepted payments are deposited immediately in the merchant's free e-money account thanks to the instant settlement feature that myPOS offers at no extra cost for its clients. The Soft POS solution can be used on Android devices that have an NFC (Near Field Communication) chip, which is present in most current smartphones. It does not require additional hardware or cables to turn the phone into a payment terminal. myPOS Glass accepts all types of credit, debit and prepaid Mastercard and Visa cards, as well as wallets like Apple Pay, Google Pay and Samsung Pay. The application meets all industry standards for data protection and security. It ensures that the cardholder's data is not

Andersen Global Extends Coverage in St. Kitts and Nevis29.10.2020 14:30:00 CETPress release

Andersen Global continues its Caribbean expansion through a Collaboration Agreement with full-service accounting firm Lanns-Monish & Associates, adding dimension to the organization’s presence in St. Kitts and Nevis. Founded in 1991, the Basseterre-based firm is led by founder and Office Managing Director Marcella Lanns-Monish. The team of ten professionals provides tax and accounting services to domestic and international clients, including business advisory, corporate restructuring, tax compliance, payroll and risk advisory. In addition, they provide services to a variety of industries, including hospitality, tourism, manufacturing and the public sector. “The dedication and stewardship of our team to provide clients with best-in-class service has helped us become leaders in our practice areas,” said Marcella. “This collaboration will allow us to take our client service to the next level and expand our reach more broadly. We are excited to work in tandem with Andersen’s collaborating

Conviva’s Latest Streaming Data Shows Advertisers Beginning to Reemerge; Rise of Smart TVs Slows Growth for Connected TV Devices29.10.2020 14:00:00 CETPress release

Conviva, the leader in global streaming media intelligence, released its quarterly State of Streaming report for Q3 2020 today, showing a 57% year over year increase in overall viewing time, continuing the trend of multiple quarters of strong streaming growth. The report also uncovered new streaming trends including the long-awaited return of advertisers and the increasing battle between smart TVs and connected TV devices such as Roku. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005174/en/ Conviva's State of Streaming - Q3 2020 (Graphic: Business Wire) “Streaming has exploded in the past year as illustrated by content like the NFL which saw 41% growth on streaming and remained relatively flat on linear TV,” said Bill Demas, CEO, Conviva. “As a result, we are seeing more investment in streaming services, advertisers shifting to streaming platforms and consumers adopting streaming-enabled devices and TVs at a rapid pa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom